Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Paul F. Wheatley-Price"'
Autor:
Parneet K. Cheema, Shantanu O. Banerji, Normand Blais, Quincy S.-C. Chu, Rosalyn A. Juergens, Natasha B. Leighl, Adrian Sacher, Brandon S. Sheffield, Stephanie Snow, Mark Vincent, Paul F. Wheatley-Price, Stephen Yip, Barbara L. Melosky
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6473-6496 (2023)
Activating mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS), in particular, a point mutation leading to a glycine-to-cysteine substitution at codon 12 (G12C), are among the most frequent genomic alterations in non-small cell lung canc
Externí odkaz:
https://doaj.org/article/ab0cb512b2d24cbeafaef622627ed0b6
Autor:
Barbara L. Melosky, Natasha B. Leighl, David Dawe, Normand Blais, Paul F. Wheatley-Price, Quincy S.-C. Chu, Rosalyn A. Juergens, Peter M. Ellis, Alexander Sun, Devin Schellenberg, Diana N. Ionescu, Parneet K. Cheema
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6289-6315 (2023)
Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high relapse rates, and significant morbidity and mortality. Apart from advances in radiation therapy, progress in the systemic treatment of SCLC had been stagnant for over th
Externí odkaz:
https://doaj.org/article/4018347cac8e41ddb2d0bdfcb844469e
Autor:
Parneet K. Cheema, Shantanu O. Banerji, Normand Blais, Quincy S.-C. Chu, Patrice Desmeules, Rosalyn A. Juergens, Natasha B. Leighl, Brandon S. Sheffield, Paul F. Wheatley-Price, Barbara L. Melosky
Publikováno v:
Current Oncology, Vol 28, Iss 6, Pp 4552-4576 (2021)
In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatment
Externí odkaz:
https://doaj.org/article/cff2cd04e5ec4ee7b2c71fd057ff1e6b